Email Alert | RSS

北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (5): 892-896. doi: 10.19723/j.issn.1671-167X.2020.05.016

• 论著 • 上一篇    下一篇

Semaphorin 3A在系统性红斑狼疮合并血小板减少患者中的水平及意义

郭倩1,2*,马晓旭1*,高辉2,石连杰2,钟昱超1,谢琳峰1,邵苗1,张学武1,∆()   

  1. 1.北京大学人民医院风湿免疫科,北京 100044
    2.北京大学国际医院风湿免疫科,北京 102206
  • 收稿日期:2018-07-09 出版日期:2020-10-18 发布日期:2020-10-15
  • 通讯作者: 张学武 E-mail:xuewulore@163.com
  • 基金资助:
    国家自然科学基金(81501396)

Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus

Qian GUO1,2*,Xiao-xu MA1*,Hui GAO2,Lian-jie SHI2,Yu-chao ZHONG1,Lin-feng XIE1,Miao SHAO1,Xue-wu ZHANG1,∆()   

  1. 1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
  • Received:2018-07-09 Online:2020-10-18 Published:2020-10-15
  • Contact: Xue-wu ZHANG E-mail:xuewulore@163.com
  • Supported by:
    National Natural Science Foundation of China(81501396)

RICH HTML

 10   

PDF (PC)

300

摘要：

目的:通过测定血清Semaphorin 3A(Sema3A)的水平,分析Sema3A与系统性红斑狼疮(systemic lupus erythematosus,SLE)血小板减少的相关性。方法: 应用酶联免疫吸附法检测170例SLE患者、50例干燥综合征(Sjögren’s syndrome,SS)患者、19例脾功能亢进(hypersplenism,HS)患者及150例健康对照(healthy controls,HC)血清中Sema3A的水平,收集患者及健康对照的临床资料及实验室检查,实验室检查主要为患者的血常规及骨髓穿刺活检结果。根据是否合并血小板减少及血小板减少是否缓解,将SLE患者分为SLE合并血小板减少组(41例)、SLE合并血小板减少缓解组(28例)及SLE未合并血小板减少组(101例)。根据是否合并血小板减少,将SS患者分为SS合并血小板减少组(18例)及SS未合并血小板减少组(32例)。将28例进行骨髓穿刺活检的SLE患者,根据骨髓象结果从骨髓增生情况方面将其分为骨髓增生正常组(19例)和增生减低组(9例),从巨核细胞成熟方面将其分为有巨核细胞成熟障碍组(8)和无巨核细胞成熟障碍组(20例)。比较各组Sema3A水平差异,并分析各组患者血清Sema3A水平与血小板的相关性及不同骨髓象间血清Sema3A的水平。结果: (1)SLE患者血清Sema3A水平较HC显著降低[(3.84±2.76) μg /L vs. (6.96±2.62) μg/L,P<0.001],SS患者血清Sema3A水平亦较HC显著降低[(4.35±3.57) μg/L vs. (6.96±2.62) μg/L,P<0.001],HS患者血清Sema3A水平较HC也明显降低[(5.67±2.26) μg/L vs. (6.96±2.62) μg/L,P=0.041]。(2)SLE患者血清Sema3A水平较SS患者降低,但差异无统计学意义[(3.84±2.76) μg/L vs. (4.35±3.57) μg/L,P=0.282],SLE患者血清Sema3A水平与HS患者相比显著降低,差异有统计学意义[(3.84±2.76) μg/L vs. (5.67±2.26) μg/L,P=0.006]。(3)SLE合并血小板减少组Sema3A水平显著低于SLE合并血小板减少缓解组[(1.28±1.06) μg/L vs. (3.83±2.65) μg/L,P<0.001]和SLE未合并血小板减少组[(1.28±1.06) μg/L vs. (4.87±2.60) μg/L,P<0.001],而SLE合并血小板减少缓解组与SLE未合并血小板减少组相比,差异无统计学意义[(3.83±2.65) μg/L vs. (4.87±2.60) μg/L,P=0.123]。SLE合并血小板减少组患者Sema3A水平与SS合并血小板减少组患者相比降低,但差异无统计学意义[(1.28±1.06) μg/L vs. (1.68±1.11) μg/L,P=0.189]。(4)相关性分析显示SLE患者的Sema3A水平与血小板显著相关(r=0.600,P<0.001), SS患者的Sema3A水平与血小板亦呈明显的正相关(r=0.573,P<0.001),但HS患者与Sema3A却没有表现出明显的相关性(P=0.393)。(5)血清Sema3A在骨髓增生正常和减低的SLE患者,及有和无巨核细胞成熟障碍的SLE患者中的水平差异无统计学意义(P>0.05)。结论:血清Sema3A在多种合并血小板减少的疾病中水平普遍下降,SLE患者血清Sema3A水平显著降低,并与血小板呈明显正相关,在SS患者中亦可得出类似结论,提示Sema3A与结缔组织病的血小板减少相关。

关键词: Semaphorin 3A, 红斑狼疮, 系统性, 血小板减少

Abstract:

Objective: To measure the level of serum Semaphorin 3A (Sema3A) and to analyze the relationship between serum Sema3A and systemic lupus erythematosus (SLE) with thrombocytopenia. Methods: The concentration of serum Sema3A was detected by enzyme-linked immuno sorbent assay (ELISA) in 170 SLE patients, 50 Sjögren’s syndrome (SS) patients, 19 hypersplenism (HS) patients and 150 healthy controls (HC). Based on the presence of thrombocytopenia and whether the thrombocytopenia was in remission, the SLE patients were divided into three groups: SLE with thrombocytopenia (41 cases), SLE with thrombocytopenia remission (28 cases), and SLE without thrombocytopenia (101 cases). According to whether there was thrombocytopenia, the SS patients were divided into SS with thrombocytopenia (18 cases) and SS without thrombocytopenia (32 cases). The 28 SLE patients who underwent bone marrow aspiration biopsy were divided into two groups from the aspect of whether the bone marrow hyperplasia was normal (19 cases) or low (9 cases), as well as from the aspect of whether the maturity disturbance of megakaryocyte was positive (8 cases) or negative (20 cases). The serum Sema3A levels in SLE, SS, HS with HC were compared, meanwhile, the correlation between serum Sema3A level and platelet (PLT) in the patients with different diseases analyzed. Results: (1) Serum Sema3A levels in SLE were significantly lower than in HC [(3.84±2.76) μg/L vs. (6.96±2.62) μg/L, P<0.001], serum Sema3A levels in SS were also obviously lower than in HC [(4.35±3.57) μg/L vs. (6.96±2.62) μg/L, P<0.001], and in HS it was lower than HC at a certain extant [(5.67±2.26) μg/L vs. (6.96±2.62) μg/L, P=0.041]. (2) Serum Sema3A levels in SLE were slightly lower than in SS, but there was no significant difference [(3.84±2.76) μg/L vs. (4.35±3.57) μg/L, P=0.282]. However, when compared with HS, serum Sema3A levels in SLE were significantly lower [(3.84±2.76) μg/L vs. (5.67±2.26) μg/L, P=0.006]. (3) Serum Sema3A concentration in SLE with thrombocytopenia was significantly lower than in SLE with thrombocytopenia remission [(1.28±1.06) μg/L vs. (3.83±2.65) μg/L, P<0.001], and in SLE patients without thrombocytopenia [(1.28±1.06) μg/L vs. (4.87±2.60) μg/L, P <0.001]. There was no significant difference between SLE with thrombocytopenia remission and SLE without thrombocytopenia [(3.83±2.65) μg/L vs. (4.87±2.600 μg/L, P=0.123]. Serum Sema3A concentration in SLE with thrombocytopenia was slightly lower than in SS with thrombocytopenia, but there was no significant difference [(1.28±1.06) μg/L vs. (1.68±1.11) μg/L, P=0.189]. (4) Strong positive correlations were found between serum Sema3A and PLT in SLE (r=0.600, P<0.001). Positive correlations were also found between serum Sema3A and PLT in SS (r=0.573, P<0.001). However, there was no such correlation showed in HS patients (P=0.393). (5) There was no significant difference of serum Sema3A concentration in SLE whether the bone marrow hyperplasia was normal or low. And the same situation appeared in the patients whether the maturity disturbance of megakaryocyte was positive or negative (P>0.05). Conclusion: Serum Sema3A was significantly reduced in SLE patients, and it was highly correlated with the blood damage. Similar conclusions could be drawn in patients with SS. The serum level of Sema3A was generally decreasing in desmosis which merged thrombocytopenia, and was obviously positive correlated with platelet counts.

Key words: Semaphorin 3A, Lupus erythematosus, systemic, Thrombocytopenia

中图分类号: 

  • R593.24

表1

各组研究对象的一般资料及血清Sema3A水平"

Groups n Age/years Male/Female, n PLT/(×109/L) Sema3A/(μg/L) P*
SLE 170 34.49±14.53 22/148 163.88±88.61 3.84±2.76 <0.001
SS 50 51.63±13.13 6/44 125.84±74.90 4.35±3.57 <0.001
HS 19 57.58±11.16 11/8 51.0(11.0-116.0) 5.67±2.26 0.041
HC 150 42.05±12.82 31/119 6.96±2.62

图1

SLE、SS和HS患者血清Semaphorin 3A水平与血小板计数的相关性分析"

图2

不同骨髓象间血清Semaphorin 3A的水平"

[1] Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition[J]. Immunity, 2008,28(3):402-413.
doi: 10.1016/j.immuni.2008.01.012
[2] Ji JD, Park-Min KH, Ivashkiv LB. Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages[J]. Hum Immunol, 2009,70(4):211-217.
doi: 10.1016/j.humimm.2009.01.026
[3] Lepelletier Y, Moura IC, Hadj-Slimane R, et al. Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization[J]. Eur J Immunol, 2006,36(7):1782-1793.
doi: 10.1002/eji.200535601 pmid: 16791896
[4] Catalano A, Caprari P, Moretti S, et al. Semaphorin 3A is expressed by tumor cells and alters T-cell signal transduction and function[J]. Blood, 2006,107(8):3321-3329.
doi: 10.1182/blood-2005-06-2445 pmid: 16380453
[5] Vadasz Z, Haj T, Halasz K, et al. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus[J]. Arthritis Res Ther, 2012,14(3):R146.
doi: 10.1186/ar3881 pmid: 22697500
[6] Sturrock RD. Hematologic disorders in rheumatic disease[J]. Curr Opin Rheumatol, 1991,3(1):172.
doi: 10.1097/00002281-199102000-00024 pmid: 2043444
[7] Kashiwagi H, Shiraga M, Kato H, et al. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A[J]. Blood, 2005,106(3):913-921.
doi: 10.1182/blood-2004-10-4092 pmid: 15831706
[8] 高辉, 马晓旭, 郭倩, 等. Sema3A在系统性红斑狼疮患者血清及单个核细胞中的表达[J]. 中华医学杂志, 2017,97(5):370-374.
[9] Okuno T, Nakatsuji Y, Kumanogoh A. The role of immune semaphorins in multiple sclerosis[J]. FEBS Lett, 2011,585(23):3829-3835.
doi: 10.1016/j.febslet.2011.03.033
[10] Eixarch H, Gutierrez-Franco A, Montalban X, et al. Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis[J]. Trends Mol Med, 2013,19(3):157-164.
doi: 10.1016/j.molmed.2013.01.003 pmid: 23419749
[11] Takagawa S, Nakamura F, Kumagai K, et al. Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis[J]. BMC Musculoskelet Disord, 2013,14:40.
doi: 10.1186/1471-2474-14-40 pmid: 23343469
[12] Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein Ⅱb/Ⅲa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura[J]. Blood, 2003,101(2):621-623.
doi: 10.1182/blood-2002-07-2157 pmid: 12393517
[13] Shenoy S, Mohanakumar T, Chatila T, et al. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias[J]. Clin Immunol, 2001,99(2):266-275.
doi: 10.1006/clim.2001.5017
[14] Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chro-nic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response[J]. Blood, 2004,103(7):2645-2647.
doi: 10.1182/blood-2003-07-2268 pmid: 14670926
[15] Ling Y, Cao X, Yu Z, et al. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome [J]. Eur J Haematol, 2007,79(4):310-316.
doi: 10.1111/j.1600-0609.2007.00917.x pmid: 17692100
[16] Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J]. Nat Med, 2003,9(9):1123-1124.
doi: 10.1038/nm921 pmid: 12937414
[17] Wannemacher KM, Wang L, Zhu L, et al. The role of sema-phorins and their receptors in platelets: Lessons learned from neuronal and immune synapses[J]. Platelets, 2011,22(6):461-465.
doi: 10.3109/09537104.2011.561891
[1] 田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087.
[2] 邹健梅,武丽君,罗采南,石亚妹,吴雪. 血清25-羟维生素D与系统性红斑狼疮活动的关系[J]. 北京大学学报（医学版）, 2021, 53(5): 938-941.
[3] 李正芳,吴雪,武丽君,罗采南,石亚妹,钟岩,陈晓梅,孟新艳. Rhupus综合征的临床特点[J]. 北京大学学报（医学版）, 2021, 53(5): 933-937.
[4] 马向波,张学武,贾汝琳,高颖,刘洪江,刘玉芳,李英妮. 外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用[J]. 北京大学学报（医学版）, 2021, 53(4): 721-727.
[5] 夏芳芳,鲁芙爱,吕慧敏,杨国安,刘媛. 系统性红斑狼疮伴间质性肺炎的临床特点及相关因素分析[J]. 北京大学学报（医学版）, 2021, 53(2): 266-272.
[6] 石茂静,高伟波,黄文凤,朱继红. 61例血栓性血小板减少性紫癜患者的临床分析[J]. 北京大学学报（医学版）, 2021, 53(1): 210-214.
[7] 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报（医学版）, 2020, 52(6): 1009-1013.
[8] 耿研,李伯睿,张卓莉. 系统性红斑狼疮患者有症状关节病变的肌肉骨骼超声特点[J]. 北京大学学报（医学版）, 2020, 52(1): 163-168.
[9] 李英妮,相晓红,赵静,李云,孙峰,王红彦,贾汝琳,胡凡磊. 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报（医学版）, 2019, 51(6): 1019-1024.
[10] 王玉华,张国华,张令令,罗俊丽,高兰. 系统性红斑狼疮合并自发性肾上腺出血1例[J]. 北京大学学报（医学版）, 2019, 51(6): 1178-1181.
[11] 朱红林,杜倩,谌威霖,左晓霞,李全贞,刘思佳. 系统性硬化症血清细胞因子表达谱变化及调控机制[J]. 北京大学学报（医学版）, 2019, 51(4): 716-722.
[12] 杨娇,姚海红,莫晓冬,罗增,白玛央金. 我国西藏地区(高原)系统性红斑狼疮患者临床及免疫学特征分析[J]. 北京大学学报（医学版）, 2018, 50(6): 1004-1008.
[13] 张晓慧,邓雪蓉,李凡,朱颖,张卓莉. 系统性红斑狼疮合并可逆性后部脑病综合征1例[J]. 北京大学学报（医学版）, 2018, 50(6): 1102-1107.
[14] 刘爽,郭雨龙,杨静逸,王维,徐健. 间充质干细胞治疗系统性红斑狼疮有效性的meta分析[J]. 北京大学学报（医学版）, 2018, 50(6): 1014-1021.
[15] 杨帆,周云杉,贾园. 系统性红斑狼疮合并获得性血友病A 1例[J]. 北京大学学报（医学版）, 2018, 50(6): 1108-1111.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报（医学版）, 2009, 41(3): 376 -379 .
[2] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报（医学版）, 2010, 42(1): 82 -84 .
[3] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 319 -322 .
[4] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报（医学版）, 2007, 39(3): 333 -336 .
[5] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报（医学版）, 2007, 39(3): 337 -340 .
[6] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报（医学版）, 2007, 39(4): 346 -350 .
[7] 韩金涛, 赵军, 栾景源, 张龙. 多发结核性腹主动脉瘤一例[J]. 北京大学学报（医学版）, 2007, 39(4): 361 -364 .
[8] 张鲁锋, 肖锋, 李岩, 王进, 杨阳, 石志辉. 冠心病合并二尖瓣关闭不全的手术治疗效果[J]. 北京大学学报（医学版）, 2007, 39(4): 420 -422 .
[9] 赵鸿, 万峰. 骨髓细胞移植联合激光心肌血运重建及冠状动脉旁路移植术治疗缺血性心脏病[J]. 北京大学学报（医学版）, 2007, 39(4): 432 -433 .
[10] 李军, 于涛. 上消化道出血合并截瘫一例[J]. 北京大学学报（医学版）, 2007, 39(4): 440 -442 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部